Preferred Stock Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards
Quotes delayed 20 minutes



If the video does not load after a few moments, Upgrade to the Latest Flash Player.
www.valueforum.com/7/
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow The 10 Highest Yielding Preferred Stocks

By Preferred Stock Channel Staff, updated Wednesday, July 27, 7:29 AM

#10. Cyclacel Pharmaceuticals, Inc | 6% Convertible Exchangeable Preferred Stock (NASDAQ:CYCCP) | 10.17% CURRENT YIELD

Discount to Liquidation Preference: -41.00%Average Discount in Category: -26.41%
Current Annualized Yield: 10.17%Average Yield in Category: 8.21%
Days Since Last Ex-Div Date: 102 | See Dividend History »Categorization: Drugs & Pharmaceuticals

Redeemable?:Yes
Call Date:11/6/2007 (Now Trading Post Call Date)
Perpetual?:Yes
Cumulative?:Yes
Conversion Ratio:4.2553
Conversion Price:$2.35
Shares Offered:2600000
Overallotment:390000
Liquidation Preference:$10
Recent Market Price:$6.10
Discount to Liquidation Preference:
(More Preferreds Trading at a Discount »)
$-3.90 (-39.00%)
Annualized Dividend:0.60
Recent Ex-Date:4/14/2016
Current Yield:9.84%
Original Coupon:6.0000%
Pay Period:Quarterly
Pay Dates:1-Feb, 1-May, 1-Aug, 1-Nov
Cyclacel Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of small molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Co. is focused on hematology and oncology based on a development pipeline of novel drug candidates. Co.'s primary candidate, sapacitabine, is an orally-available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as chemotherapies. In its second development program, Co. is evaluating cyclin dependent kinase (CDK) inhibitors. Seliciclib, is Co.'s primary CDK inhibitor.

Preferred: CYCCP


Open the CYCC Information Page »
Name:  Cyclacel Pharmaceuticals, Inc
Website:  www.cyclacel.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CYCC:  1 (see which ones)
Total Market Value Held by ETFs:  $3,867
Total Market Capitalization:  $14,000,000
% of Market Cap. Held by ETFs:  0.03%

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

The 10 Highest Yielding Preferred Stocks - Slide 1 of 10 | www.PreferredStockChannel.com | Copyright © 2011 - 2016, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.